Sosei Heptares (the corporate brand of Sosei Group Corporation) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).
Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected StaR® technology and platform.
Our primary focus is the discovery and early development of new medicines originating from our proprietary G Protein-Coupled Receptor (GPCR)-targeted StaR® technology and Structure-Based Drug Design (SBDD) platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.
We have established partnerships with some of the world’s leading pharmaceutical companies, including Abbvie, AstraZeneca, Genentech (Roche), Novartis, Pfizer and Takeda; and additionally, with multiple emerging biotechnology companies.
Sosei Heptares has approximately 145 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development
Sosei Heptares currently has an opportunity for a talented and creative scientist to join the Drug Metabolism and Pharmacokinetics (DMPK) group to act as an expert in the discipline and Project Representative on Drug Discovery project teams. The position will be at the level of Senior Scientist or Principal Scientist depending on experience. Sosei Heptares has a strong and diverse discovery pipeline covering multiple therapeutic areas (TAs) and has several assets moving towards clinical development which are aimed at delivering innovative life changing medicines. In this role you will be responsible for designing in vitro and in vivo ADME experiments to ensure that appropriate strategies are in place to transition early hits through to preclinical candidates. You will work closely with project leaders and actively collaborate with other discipline leaders on project teams to ensure delivery of high-quality candidates. In this role there will be opportunity to promote the use of modelling and simulation and play an important role in shaping the future growth of DMPK and Translational Sciences.
The role would encompass:
Applicants must be able to demonstrate proof of the right to work in the United Kingdom
We offer a competitive salary, commensurate with qualifications and experience, and benefits package including pension and healthcare schemes.
The successful candidate will be employed by Heptares Therapeutics Ltd, a UK wholly owned subsidiary of Sosei Group Corporation.
Applications should include a covering letter, providing a short description of the background to their interest in the role, with curriculum vitae including the names and contact details for two referees. Please send your application in pdf format, quoting reference number 2020/2TS.
The closing date for applications is 30th June 2020.
Strictly no agencies.